RLMD Stock Summary and Trading Ideas (Relmada Therapeutics | NASDAQ:RLMD)

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Relmada Therapeutics trades on the NASDAQ stock market under the symbol RLMD.

As of September 14, 2026, RLMD stock price declined to $4.44 with 1,185,202 million shares trading.

RLMD has a beta of 0.62, meaning it tends to be less sensitive to market movements. RLMD has a correlation of 0.01 to the broad based SPY ETF.

RLMD has a market cap of $473.61 million. This is considered a Small Cap stock.

In the last 3 years, RLMD traded as high as $8.00 and as low as $.24.

The top ETF exchange traded funds that RLMD belongs to (by Net Assets): VTI, IWM, VXF, XPH, IWO.

RLMD has outperformed the market in the last year with a price return of +192.1% while the SPY ETF gained +16.8%. However, in the short term, RLMD had mixed performance relative to the market. It has underperformed in the last 3 months, returning -31.9% vs +3.4% return in SPY. But in the last 2 weeks, RLMD shares have fared better than the market returning +2.5% compared to SPY -1.1%.

RLMD support price is $4.35 and resistance is $4.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RLMD shares will trade within this expected range on the day.